Aytu BioPharma (AYTU) 10-Q2024 Q2 Quarterly report

Filed: 14 Feb 24, 4:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absolute, accrual, apparent, breakdown, commodity, conceived, conference, coupled, data, denied, detail, detailed, driver, entry, fact, faulty, footnote, fraud, impracticable, inflation, judge, launch, likelihood, liquidity, magistrate, manual, omitted, passing, readily, Regulation, resource, respectfully, RSU, simple, succeed, system, thousand, uncertainty

Removed: alleging, automatically, base, Canada, card, Center, compound, conformity, consented, consummation, continuing, country, covenant, cover, coverage, Critical, deemed, designated, develop, digit, endotracheal, esophageal, exclusivity, expiration, FDA, field, FlutiCare, infringement, integration, ix, joining, light, medical, nasopharyngeal, NDA, oral, partial, paying, polistirex, pre, ratio, receipt, recent, remeasured, repayment, requirement, satisfaction, scenario, Shire, subset, swingline, tablet, thereof, ultraviolet, valid, vi, vii, viii, Waiver, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated AYTU transcripts

AYTU similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I Joshua R. Disbrow, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10‑Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10‑Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.

Date: February 14, 2024


	By:	/s/ Joshua R. Disbrow
		Joshua R. Disbrow
		Chairman and Chief Executive Officer
		(Principal Executive Officer)

I Mark K. Oki, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10‑Q of Aytu BioPharma, Inc. for the fiscal quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10‑Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.

Date: February 14, 2024


	By:	/s/ Mark K. Oki
		Mark K. Oki
		Chief Financial Officer
		(Principal Financial Officer)
		(Principal Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.